Clinical trials
Pancreatic Neoplasms trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
187 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2010 | 5 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 13 |
| 2017 | 11 |
| 2018 | 18 |
| 2019 | 23 |
| 2020 | 14 |
| 2021 | 20 |
| 2022 | 22 |
| 2023 | 27 |
| 2024 | 10 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 187 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 18 |
| Peking Union Medical College Hospital | 13 |
| Changhai Hospital | 12 |
| Tianjin Medical University Cancer Institute and Hospital | 9 |
| Chinese PLA General Hospital | 7 |
| First Affiliated Hospital Xi'an Jiaotong University | 6 |
| RenJi Hospital | 6 |
| Ruijin Hospital | 6 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 6 |
| Betta Pharmaceuticals Co., Ltd. | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pancreatic Neoplasms | 187 |
| Stomach Neoplasms | 19 |
| Colorectal Neoplasms | 16 |
| Liver Neoplasms | 12 |
| Lung Neoplasms | 12 |
| Breast Neoplasms | 11 |
| Ovarian Neoplasms | 9 |
| Esophageal Neoplasms | 8 |
| Carcinoma, Hepatocellular | 6 |
| Cholangiocarcinoma | 6 |
Trials
Showing 1 to 25 of 187. Each trial links to its page on Pharma Observatory.
87 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.